scholarly journals Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population

2007 ◽  
Vol 204 (6) ◽  
pp. 1295-1301 ◽  
Author(s):  
David Dynnes Ørsted ◽  
Stig Egil Bojesen ◽  
Anne Tybjærg-Hansen ◽  
Børge Grønne Nordestgaard
Keyword(s):  
Tumor Suppressor ◽  
General Population ◽  
Cancer Survival ◽  
P53 Protein ◽  
Tumor Suppressor P53 ◽  
Life Threatening ◽  
Diagnosis Of Cancer ◽  
Functional Single Nucleotide Polymorphism ◽  
Risk Of Cancer

p53 is an important tumor suppressor, normally preventing cancer development via apoptosis. A genomic Arg72Pro substitution in the p53 protein has important influence on cell death via apoptosis, which could be beneficial. We therefore tested the hypotheses that this polymorphism influences longevity, survival after a cancer diagnosis, and risk of cancer in the general population. We examined a cohort of 9,219 participants ages 20–95 from the Danish general population with 100% follow-up. The overall 12-yr survival was increased in p53 Arg/Pro heterozygotes with 3% (P = 0.003) and in Pro/Pro homozygotes with 6% (P = 0.002) versus Arg/Arg homozygotes, corresponding to an increase in median survival of 3 yr for Pro/Pro versus Arg/Arg homozygotes. We also demonstrated an increased survival after the development of cancer, or even after the development of other life-threatening diseases, for Pro/Pro versus Arg/Arg homozygotes. The Arg72Pro substitution did not associate with decreased risk of cancer. In conclusion, in this large cohort from the general population, we show that a well-known functional single nucleotide polymorphism in the tumor suppressor p53 protein leads to increased longevity, but not to decreased risk of cancer. The increased longevity may be due to increased survival after a diagnosis of cancer or other life-threatening diseases.

scholarly journals Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population

2007 ◽  
Vol 177 (5) ◽  
pp. i14-i14
Author(s):  
David Dynnes Ørsted ◽  
Stig Egil Bojesen ◽  
Anne Tybjærg-Hansen ◽  
Børge Grønne Nordestgaard
Keyword(s):  
Tumor Suppressor ◽  
General Population ◽  
Cancer Survival ◽  
Tumor Suppressor P53 ◽  
Risk Of Cancer ◽  
P53 Arg72pro Polymorphism

scholarly journals Cancer risk after total hip replacements. A prospective study of 41,402 patients in the Norwegian Arthroplasty Register linked to the Cancer Registry of Norway

2020 ◽  
Author(s):  
Eva Dybvik ◽  
Ove Furnes ◽  
Leif I. Havelin ◽  
Sophie D. Fosså ◽  
Clement Trovik ◽  
...  
Keyword(s):  
General Population ◽  
Cancer Risk ◽  
Cancer Registry ◽  
Arthroplasty Register ◽  
Total Hip ◽  
Total Hip Replacements ◽  
Hip Replacements ◽  
Risk Of Cancer ◽  
Norwegian Arthroplasty Register

Abstract Background Concerns have been raised that implants used in total hip replacements (THR) could lead to a future increased cancer risk. Several different materials and metals are used in joint prosthesis, as well as different fixation techniques and types of articulation for the surface of the joint can lead to an increased escape of particles or ions into the human body. Methods Patients with THR registered in the Norwegian Arthroplasty Register during 1987-2009 were linked to the Cancer registry of Norway. Patients with THR due to osteoarthritis, under the age of 75 at time of surgery, were included. Standardized incidence ratios (SIR) were applied to compare cancer risk for THR patients to the general population. Types of THR were divided into cemented (both components), uncemented (both components), and hybrid (cemented femoral and uncemented acetabular component). To account for selection mechanisms, time dependent covariates were applied in Cox-regression, adjusting for cancer risk the first 10 years after surgery. The analyses were adjusted for age, gender, and if the patient had additional THR-surgery in the same or the opposite hip. The study is according to the STROBE guidelines.Results When comparing patients with THR to the general population in Norway we found no differences in the risk. The overall SIR for the THR-patients after 10 years of follow-up was 1.02 (95% CI: 0.97-1.07). For cemented THR, the SIR after 10 years of follow-up was 0.99 (95% CI: 0.94-1.05), while it was 1.16 (95% CI: 1.02-1.30) for uncemented THRs, and 1.12 (95% CI: 0.91-1.33) for hybrid THRs. Adjusted Cox analyses showed that patients with uncemented THRs had an elevated risk of cancer (hazard ratio: HR=1.24, 95% CI: 1.05-1.46, p=0.009) when compared to patients with cemented THRs after 10 years of follow-up. The risk for patients with hybrid THRs was not significantly increased (HR=1.07, 95% CI: 0.85-1.35, p=0.55) compared to patients with cemented THRs. Conclusions We found that receiving an uncemented THR was associated with a small increased risk of cancer, in particular prostate cancer for younger men.

scholarly journals Psychological traumatic events in the recent past and association with diagnosis of cancer

2021 ◽  
Vol 3 (4) ◽  
pp. 96-102
Author(s):  
Fasiha Shah ◽  
Faisal Hyder Shah
Keyword(s):  
Cancer Patients ◽  
Psychological Trauma ◽  
High Rate ◽  
Close Relative ◽  
Snowball Sampling ◽  
Immune System Dysfunction ◽  
Diagnosis Of Cancer ◽  
One Year ◽  
Risk Of Cancer

Emotional stress due to psychological trauma  causes immune system dysfunction resulting in high risk of development of cancer. The study aimed to correlation psychological trauma in the past five years of cancer diagnosis. This study was a community based survey including cancer patients diagnosed with different cancers undergoing treatment or follow-up by using snowball sampling and questionnaire based technique.  The study was conducted during a period of one year from December 2019 till December 2020. All recruited patients were requested for an interview. The results of the study showed a high rate of major psychological trauma among cancer patients. Sudden death of a close relative with and without trauma of natural disaster were high. The study conclude that risk of cancer development rises with major emotional trauma specially death of a close relative.  

Expression of the Antiapoptotic Protein bcl-2 Is Not Dependent on the Tumor Suppressor p53 Protein in Indian Breast Carcinoma

Pathobiology ◽  
1997 ◽  
Vol 65 (2) ◽  
pp. 108-112 ◽  
Author(s):  
Lakshmi Kesari ◽  
V.G. Chellam ◽  
Jayaprakash Madhavan ◽  
P.P. Nair ◽  
Krishnan Nair ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Tumor Suppressor ◽  
P53 Protein ◽  
Tumor Suppressor P53 ◽  
Antiapoptotic Protein

scholarly journals Toward Cancer Diagnostics of the Tumor Suppressor p53 by Surface Enhanced Raman Spectroscopy

Sensors ◽  
2020 ◽  
Vol 20 (24) ◽  
pp. 7153
Author(s):  
Anna Rita Bizzarri ◽  
Salvatore Cannistraro
Keyword(s):  
Raman Spectroscopy ◽  
Tumor Suppressor ◽  
P53 Protein ◽  
Surface Enhanced Raman Spectroscopy ◽  
Cancer Diagnostics ◽  
Clinical Diagnostics ◽  
Tumor Suppressor P53 ◽  
Wild Type ◽  
Surface Enhanced ◽  
Surface Enhanced Raman

The tumor suppressor p53 protein plays a crucial role in many biological processes. The presence of abnormal concentrations of wild-type p53, or some of its mutants, can be indicative of a pathological cancer state. p53 represents therefore a valuable biomarker for tumor screening approaches and development of suitable biosensors for its detection deserves a high interest in early diagnostics. Here, we revisit our experimental approaches, combining Surface Enhanced Raman Spectroscopy (SERS) and nanotechnological materials, for ultrasensitive detection of wild-type and mutated p53, in the perspective to develop biosensors to be used in clinical diagnostics. The Raman marker is provided by a small molecule (4-ATP) acting as a bridge between gold nanoparticles (NPs) and a protein biomolecule. The Azurin copper protein and specific antibodies of p53 were used as a capture element for p53 (wild-type and its mutants). The developed approaches allowed us to reach a detection level of p53 down to 10−17 M in both buffer and serum. The implementation of the method in a biosensor device, together with some possible developments are discussed.

scholarly journals The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro

Oncogene ◽  
1999 ◽  
Vol 18 (17) ◽  
pp. 2690-2702 ◽  
Author(s):  
Andrew R Cuddihy ◽  
Andrew Hoi-Tao Wong ◽  
Nancy Wai Ning Tam ◽  
Suiyang Li ◽  
Antonis E Koromilas
Keyword(s):  
Protein Kinase ◽  
Tumor Suppressor ◽  
P53 Protein ◽  
Tumor Suppressor P53 ◽  
Double Stranded Rna ◽  
Serine 392
Sign in / Sign up

Export Citation Format

Share Document